HOME   REGISTER   LOGIN   HELP   PRIVACY POLICY  
       Advanced Search
  More Information
Cordis Corporation
 
 
Related Information
Cordis Cardiology Product Catalog 2004
Endovascular/Neurovascular March 2003 Product Catalog
Reimbursement Information
2003 Endovascular Reimbursement Guide
Cardiology Payment and Reimbursement Guidelines
Company Information
Cordis Environmental Policy
News and Articles
July 7, 2003 - Dear Colleague Letter on SAT
Nov. 2003 - Dear Patient Letter on SAT
Nov. 2003 - Q&A regarding SATs
Press Release
Jan. 19, 2004 - 15,000-Patient Interventional Cardiology Registry to Evaluate Impact of Drug-Eluting Coronary Stents
Nov. 11, 2003 - Two-Year SIRIUS Trial Follow-up Shows Sustained Outstanding Performance of the CYPHER™ Stent
November 25, 2003 - FDA Update on SAT and Hypersensitivity Reaction with the CYPHER Stent
October 29, 2003 FDA Notice on Reported SATs and Hypersensitivity Reactions with CYPHER Stent
OPTEASE CE Press Release 05/12/03
Contact Information
Cordis Corporation

images/Cordis_products.jpg

For more than 40 years, Cordis Corporation, a Johnson & Johnson company, has pioneered less invasive treatments for vascular disease. Technological innovation and a deep understanding of the medical marketplace and the needs of patients have made Cordis the world's leading developer and manufacturer of breakthrough products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. Cordis employees worldwide share a strong commitment to continue the Company's groundbreaking work in the fight against vascular disease.